Tyra Pairs Early Bladder Cancer Signal With Funding Into 2030, Eyes 2027 Pivotal Start

Tyra Biosciences has paired a first look at clinical data for its oral FGFR3 inhibitor, dabogratinib, with a balance sheet that the company says can carry it to 2030. The US biotech disclosed both on 10 November 2026 alongside its third-quarter results.

In the Phase 2 SURF302 study, patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer (NMIBC) whose tumours carry FGFR3 alterations were given 60 mg once daily. The overall response rate was 79%. The information available to CompePharma does not specify how many patients were treated, how long responses lasted, or what side effects emerged, so the figure is hard to weigh against existing treatments.

Tyra intends to talk to health authorities about a Phase 3 adjuvant study, which it expects to start in 2027. Design, comparator and endpoints have not been disclosed. Those choices, and the regulators' views on them, will largely determine how quickly dabogratinib could reach a pivotal readout.

The financing picture is clearer. Tyra closed a public offering of about $400 million in September and reported $700.5 million in cash at the end of the quarter. The company expects that to fund operations through 2030, which would cover the planned Phase 3 start without an immediate need to return to investors.